Bioequivalence of drugs in the skin

In an FDA (Food and Drug Administration) co-funded project we have
developed a methodology to determine bioequivalence of topical drugs

Therapeutic antibody in the skin

dOFM was successfully used to measure a therapeutic antibody (secukinumab) and inflammatory markers in healthy and lesional skin of patients with psoriasis

PK of nanoformulated cancer drugs in the brain

cOFM was successfully used to measure substance transport enhanced by nanocarriers across the blood-brain barrier

Tissue selective insulin concentrations in adipose tissue

aOFM was successfully used to measure insulin concentrations and
time-resolved profiles in a clinical trial

Better data
for better decisions

Our innovative OFM (open flow microperfusion) sampling technology is a valuable tool for PK-PD studies in neuroscience, dermatology, oncology, and biomarker research. Minimally invasive, membrane-free OFM probes enable access to the entire biochemical information of the interstitial fluid from brain and peripheral tissues, and thus opens up new horizons in pre-clinical and clinical drug testing.

Efficient

OFM studies reduce costs by providing a complete pharmacological profile early in drug development.

Targeted

OFM probes enable continuous sampling from clearly specified tissue types.

Universal

OFM samples all substances from the interstitial fluid independent of size, lipophilicity or protein-binding.

Latest News

The U.S. Food and Drug Administration recently published a video showing the potential of dermal open flow microperfusion (dOFM) for generic drug development.

Contact Us

Please reach out and we will answer
your questions, react to your ideas and
deal with your requirements.

Keep in touch